z-logo
open-access-imgOpen Access
Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function
Author(s) -
Repellin Claire E.,
Ganesan Priya,
Alcudia Javier F.,
Lakshmireddy Haritha K. Duggireddy,
Patel Puja,
Beviglia Lucia,
Javitz Harold S.,
Sambucetti Lidia,
Bhatnagar Parijat
Publication year - 2020
Publication title -
advanced biosystems
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.153
H-Index - 18
ISSN - 2366-7478
DOI - 10.1002/adbi.201900224
Subject(s) - chimeric antigen receptor , cell culture , mesothelin , antigen , biology , cytolysis , monoclonal antibody , microbiology and biotechnology , cell , antibody , cancer research , computational biology , t cell , immunology , cytotoxicity , genetics , in vitro , immune system
A set of genetically engineered isogenic cell lines is developed to express either folate receptor alpha or mesothelin, and a control cell line negative for both antigens. These cell lines also express fluorescent and bioluminescent reporter transgenes. The cell lines are used to authenticate specificity and function of a T‐cell biofactory, a living vector that is developed to express proportionate amounts of engineered proteins upon engaging with disease cells through their specific antigenic biomarkers. The engineered cell lines are also used to assess the cytolytic function and specificity of primary T cells engineered with chimeric antigen receptors; and the specificity of monoclonal antibodies. The strategy described can be used to generate other cell lines to present different disease‐specific biomarkers for use as quality control tools.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom